FrameworkOperating models18 Sept 2026Six pages

Go To Market

How a medicine gets from approved to in the patient's hands, and paid for. Five questions, in the order that matters, for the Gulf and Asia.

Who this is for
General managers, commercial leads and marketing and sales teams in the Gulf, Asia and other emerging markets. Most useful if you are sizing a team, choosing a distributor, or working out why a product that is approved and listed is still not selling.

What it is, and is not

Go to market is everything between a medicine being approved and a patient actually taking it. That is it. Get that far and you have a business. Don't, and you have a registration certificate.

In scope: who pays for it, where it gets bought, who decides which brand, how many of your people are needed and doing what, whether it is actually on the shelf, and what the patient pays at the counter.

Out of scope: whether the drug works, which is clinical. Getting it registered, which is regulatory. Getting it on the list, which is access. What the brand says about itself, which is brand strategy. How it is made and shipped, which is supply.

I have read a lot of plans where go to market meant a launch campaign and a rep count. Access owned the listing. Marketing owned the message. Nobody owned the part in between, which is the part that decides whether anything sells.
Clarity

Five different people, not one customer

1

The patient

Takes it. In a cash market, also pays for it and decides whether to buy the next pack.

2

The doctor

Prescribes it. Often has no idea what it costs or whether it is covered.

3

The pharmacist

Hands it over, and very often picks the brand. Paid on margin, not on your brand.

4

The payer

Pays for it. A government, an insurer, or the patient themselves.

5

The buyer

Buys the stock. A tender body, a hospital, a pharmacy chain, a wholesaler.

Five questions, and the order matters

One. Who is my customer? Who chooses, and who buys. Two. Who pays for it? Three. How does it reach the patient? Four. Who do I need in front of them, and how many? Five. What does that cost, and does it pay?

Answer them in this order. Not because it is tidy, but because each one closes off the options for the next. Almost everyone starts at four. You have fifty reps, so the plan gets built for fifty reps, and the first three questions get answered backwards to justify a number you already had. I have done this. It cost a year.

Insured does not mean paid for.

Who really pays in these markets

In Dubai, thirty four per cent of money spent in pharmacies comes straight from the patient. In 2019 it was twenty eight per cent. Insurance is mandatory and the cash share went up. UAE basic cover pays for about AED 1,500 of medicine a year with a thirty per cent co-payment, roughly USD 400, and after that the patient pays everything. Dubai's cheapest plan cut its covered list from about 2,500 products to about 700, mostly generics.

In Indonesia, about 4,300 pharmacies out of nearly 32,000 can fill an insurance prescription. In the Philippines, ninety per cent of medicine sales go through drugstores. In India, more is spent at chemists than at government hospitals, and only fourteen per cent of adults with high blood pressure are on treatment at all.

If the patient is paying, your market is not everyone who could take the product. It is everyone who can afford to finish the course. Those two numbers are a long way apart, and only one of them is real.
Six pages

The framework in full

The definition, the five people, the five questions, the numbers, and a single page that turns who pays into your customer, channel, team and risk.

Download the PDF →

Run it against your own market

If you cannot name all five people for your product, or your team size came before your channel choice, that is the kind of thing I am useful for.

Tell me what needs to change →